Krapcho, A. Paul; Petry, Mary E.; Getahun, Zelleka; Landi, John J. Jr.; Stallman, John; Polsenberg, Johanna F.; Gallagher, Cynthia E.; Maresch, Martin J.; Hacker, Miles P. published the artcile< 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A Novel Class of Chromophore-Modified Antitumor Anthracene-9,10-diones: Synthesis and Antitumor Evaluations>, Recommanded Product: 6,9-Difluorobenzo[g]isoquinoline-5,10-dione, the main research area is anthracenedione preparation antitumor; benzoisoquinoline preparation antitumor.
Synthetic procedures have been developed which lead to the 2-aza congeners I (R = amine groups or N-containing heterocyclic groups) and several related N-oxides (II, R = NH2 or NMe2). I exhibited a wide range of in vitro cytotoxicity against L1210 leukemia, the human colon adenocarcinoma cell line LoVo, and the doxorubicin resistant LoVo/DX cell line. Selected analogs of I showed significant P388 antileukemic activity in mice with I (R = NH2, n = 2) exhibiting high activity. This activity was also retained in the related N-oxide II (R = NH2, n = 2). These heterocyclic bioisosteric models are representative of the first anthracene-9,10-diones which display antileukemic activity comparable to mitoxantrone.
Journal of Medicinal Chemistry published new progress about Antitumor agents. 144511-13-7 belongs to class isoquinoline, and the molecular formula is C13H5F2NO2, Recommanded Product: 6,9-Difluorobenzo[g]isoquinoline-5,10-dione.
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem